Elite Pharmaceuticals, Inc. (ELTP) Fair Value 2026

ELTP · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.8 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (22/100)

Quick Summary — As of 2026-08-27, Elite Pharmaceuticals, Inc. (ELTP) trades at $0.29, versus a $0.45 median fair value across its 9 active models — 56.8% above the current price. QOC: 8.8/10. Value Trap Risk: 22/100 (SAFE). 9/13 models active. Within that set, the Bayesian DCF component alone returns $0.30.

Key Facts

Ticker
ELTP
Price
$0.29
Quality Score
8.8/10
Value Trap Risk
22/100
Models Active
9/13
Last Updated
Strength: First Chicago suggests +206.1% upside with 60% confidence
Risk: Limited model coverage (9/13) may reduce confidence

Is Elite Pharmaceuticals, Inc. (ELTP) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, Elite Pharmaceuticals, Inc. (ELTP) appears undervalued as of : the median of 9 independent fair value estimates is $0.45, 56.8% above the current price of $0.29. Estimates range from $0.24 to $0.89. ELTP scores 8.8/10 on fundamental quality and 22/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. ELTP’s +56.8% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -1.4%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Elite Pharmaceuticals, Inc. Stock in 2026? →

What Fair Value Does Each Model Give ELTP?

9 Intrinsic Value Models vs. Current Price ($0.29)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.30 +3.1%
Ensemble · Medium Conviction
 $0.45 +56.8%
Scenario · High Conviction
 $0.89 +206.1%
Intrinsic · High Conviction
 $0.29 +0.7%
Unlock the Full Matrix

Access 5 additional models including ML-RIV, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is ELTP's Fair Value Range?

Spread across 9 independent models · $0.24 to $0.89

CirclFi's 9 active models place Elite Pharmaceuticals, Inc. (ELTP) between $0.24 and $0.89 per share, a spread of 143% of the median. The median of that range — $0.45 — is the fair value CirclFi publishes for ELTP, against a current price of $0.29.

Low · RCMH-DCFHigh · First Chicago
$0.24median $0.45$0.89
Where the range comes from
Most bearish modelRCMH-DCF$0.24
Most bullish modelFirst Chicago$0.89
Model agreement6 bullish · 1 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for ELTP. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on ELTP, not a CirclFi price target. How each model works →

What Is Elite Pharmaceuticals, Inc. (ELTP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, our multi-model framework produces a cautiously optimistic read on Elite Pharmaceuticals, Inc. at $0.29. With an estimated intrinsic value of $0.45 and 6 of 9 models pointing higher, the median implied return is +56.8%. The most optimistic model, First Chicago, places fair value at $0.89 (+206.1%), while RCMH-DCF — the most conservative — estimates $0.24 (-17.7%). This +223.8% gap reflects genuine analytical uncertainty about Elite Pharmaceuticals, Inc.'s intrinsic worth.

What Do the Models Say About ELTP?

9 of 13 models are currently active for ELTP. Of these, 8 models suggest upside while 1 model suggests overvaluation. Taken together, their median fair value for ELTP is $0.45 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $0.30 on its own, implying +3.1% upside from the current price. See which stocks rank higher →

How Does ELTP Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, ELTP ranks #7 by Quality of Company score. CirclFi's QOC score of 8.8/10 evaluates 32 fundamental signals. A score of 8.8 places ELTP in the top tier.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

As a pharmaceutical industry, Elite Pharmaceuticals, Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating ELTP should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ELTP a Value Trap?

CirclFi's Value Trap algorithm assigns ELTP a score of 22/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Elite Pharmaceuticals, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Elite Pharmaceuticals, Inc.'s fundamental quality profile registers 8.8/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +223.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ELTP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ELTP's 9 active models, average confidence is 49%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Elite Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

ANIPANI Pharmaceuticals, Inc.QOC 9.0RDYDr. Reddy's Laboratories LimitedQOC 8.8NBIXNeurocrine Biosciences, Inc.QOC 9.1COLLCollegium Pharmaceutical, Inc.QOC 8.8LNTHLantheus Holdings, Inc.QOC 9.3PAHCPhibro Animal Health CorporationQOC 8.7BHCBausch Health Companies Inc.QOC 6.8PRGOPerrigo Company plcQOC 5.9RAPHRaphael Pharmaceutical Inc.QOC 4.6UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: ANIP · RDY · NBIX · COLL · LNTH · PAHC · BHC · PRGO · RAPH · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to ELTP?

7 companies across all industries closest to ELTP’s Quality of Company score of 8.8/10.

ACNAccenture plcQOC 8.8TCBXThird Coast Bancshares, Inc.QOC 8.8OIIOceaneering International, Inc.QOC 8.8OSISOSI Systems, Inc.QOC 8.8TCOMTrip.com Group LimitedQOC 8.8ORRFOrrstown Financial Services, Inc.QOC 8.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ACN · TCBX · OII · OSIS · TCOM · ORRF · NVDA

Where Does ELTP Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

ELTP is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Elite Pharmaceuticals, Inc.’s Valuation?

What is Elite Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi puts Elite Pharmaceuticals, Inc. (ELTP)'s intrinsic value at $0.45 — the median of 9 independent model estimates as of 2026-08-27, ranging from $0.24 to $0.89. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $0.30 on its own. The Quality of Company score is 8.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ELTP overvalued or undervalued right now?

At $0.29, 8 of 9 active models suggest ELTP may be undervalued, while 1 indicate potential overvaluation. The median of all 9 fair value estimates is $0.45, 56.8% above the current price of $0.29 — a consensus view that ELTP is undervalued. The assessment depends on which methodology best fits Elite Pharmaceuticals, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 8.8 mean for ELTP?

Elite Pharmaceuticals, Inc.'s QOC of 8.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on ELTP?

CirclFi analyzes ELTP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on ELTP?

Of the 9 models currently active on ELTP, First Chicago is the most bullish at $0.89 per share, and RCMH-DCF is the most bearish at $0.24. CirclFi's published fair value for ELTP is the median of that range, $0.45, not either extreme. The gap between the two ends equals 143% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is ELTP a value trap in 2026?

Elite Pharmaceuticals, Inc.'s Value Trap score is 22/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 9-model valuation engine, Elite Pharmaceuticals, Inc. (ELTP) has a median fair value of $0.45 — 56.8% above the current price of $0.29 — as of 2026-08-27.” Source: circlfi.com/stock/ELTP/ · Methodology
Primary sources for this ELTP valuation
  • Financial statements: Elite Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001053369) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ELTP as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on ELTP.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

5 models hidden for ELTP Unlock All 9 — $39/mo